https://novapharmanews.com/apac/news/cell-gene-therapy-approvals-china-regulatory-updates 2026-06-03T21:59:14.359Z NovaPharmaNews en 2026-06-03T21:59:14.366Z Cell and Gene Therapy Approvals in China: Latest Regulatory Updates gene therapy https://novapharmanews.com/uploads/articles/cell-gene-therapy-approvals-china-regulatory-updates.webp Cell and Gene Therapy Approvals in China: Latest Regulatory Updates https://novapharmanews.com/eu/news/who-europe-access-novel-medicines 2026-06-03T21:53:08.433Z NovaPharmaNews en 2026-06-03T21:53:08.438Z WHO/Europe Initiative on Access to Novel Medicines: Market Implications for Pharma https://novapharmanews.com/uploads/articles/who-europe-access-novel-medicines.webp WHO/Europe Initiative on Access to Novel Medicines: Market Implications for Pharma https://novapharmanews.com/apac/news/regulatory-round-up-drug-approvals-18-may-2026 2026-06-03T21:18:13.200Z NovaPharmaNews en 2026-06-03T19:23:49.735Z Regulatory Round-Up: Key Drug Approvals on May 18, 2026 https://novapharmanews.com/uploads/articles/regulatory-round-up-drug-approvals-18-may-2026.webp Regulatory Round-Up: Key Drug Approvals on May 18, 2026 https://novapharmanews.com/eu/news/us-europe-biosimilar-approvals-2026 2026-06-03T21:43:18.705Z NovaPharmaNews en 2026-06-03T19:10:52.379Z Biosimilar Approvals: U.S. vs. Europe Insights for Pharma BD https://novapharmanews.com/uploads/articles/us-europe-biosimilar-approvals-2026.webp Biosimilar Approvals: U.S. vs. Europe Insights for Pharma BD https://novapharmanews.com/eu/news/key-cancer-drugs-esmo-2025 2026-06-03T20:30:07.804Z NovaPharmaNews en 2026-06-03T19:05:29.875Z Key Cancer Drugs to Watch at ESMO 2025: Investor and BD Insights cancer https://novapharmanews.com/uploads/articles/key-cancer-drugs-esmo-2025.webp Key Cancer Drugs to Watch at ESMO 2025: Investor and BD Insights https://novapharmanews.com/us/news/stat-trump-s-medicaid-work-requirements-have-an-unwelcome-surprise-for-some-states-and-patients 2026-06-03T21:50:32.782Z NovaPharmaNews en 2026-06-03T18:49:07.382Z STAT+: Trump’s Medicaid work requirements have an unwelcome surprise for some states and patients https://novapharmanews.com/uploads/articles/stat-trump-s-medicaid-work-requirements-have-an-unwelcome-surprise-for-some-states-and-patients.webp STAT+: Trump’s Medicaid work requirements have an unwelcome surprise for some states and patients https://novapharmanews.com/us/news/military-eating-disorders-prevalence-impact 2026-06-03T20:30:07.060Z NovaPharmaNews en 2026-06-03T18:49:06.601Z The Military's Role in the Rising Tide of Eating Disorders eating disorders https://novapharmanews.com/uploads/articles/military-eating-disorders-prevalence-impact.webp The Military's Role in the Rising Tide of Eating Disorders https://novapharmanews.com/eu/news/european-navenibart-deal-biocryst-analysis 2026-06-03T22:00:26.051Z NovaPharmaNews en 2026-06-03T18:10:13.708Z European Navenibart Deal: A Strategic Win for BioCryst's Rare Disease Portfolio Navenibart, rare disease https://novapharmanews.com/uploads/articles/european-navenibart-deal-biocryst-analysis.webp European Navenibart Deal: A Strategic Win for BioCryst's Rare Disease Portfolio https://novapharmanews.com/apac/news/risen-pharma-phase-2-trial-rp902-alzheimers 2026-06-03T21:39:27.845Z NovaPharmaNews en 2026-06-03T18:00:50.146Z Risen Pharma Initiates Phase 2 Trial for RP902 in Alzheimer's RP902, Alzheimer's disease, Mild Cognitive Impairment https://novapharmanews.com/uploads/articles/risen-pharma-initiates-phase-2-trial-for-rp902-in-alzheimer-s.webp Risen Pharma Initiates Phase 2 Trial for RP902 in Alzheimer's https://novapharmanews.com/us/news/fda-blueprint-regulatory-risk-animal-testing-alternatives 2026-06-03T20:59:22.311Z NovaPharmaNews en 2026-06-03T17:42:14.685Z FDA Blueprint Aims to Reduce Regulatory Risks for Animal Testing Alternatives https://novapharmanews.com/uploads/articles/fda-blueprint-regulatory-risk-animal-testing-alternatives.webp FDA Blueprint Aims to Reduce Regulatory Risks for Animal Testing Alternatives https://novapharmanews.com/apac/news/regulatory-updates-optical-coherence-tomography-pharma 2026-06-03T17:20:33.409Z NovaPharmaNews en 2026-06-03T17:18:44.483Z Optical Coherence Tomography Gains Regulatory Traction in Pharma Filings https://novapharmanews.com/uploads/articles/regulatory-updates-optical-coherence-tomography-pharma.webp Optical Coherence Tomography Gains Regulatory Traction in Pharma Filings https://novapharmanews.com/us/news/china-drug-development-oncology-us 2026-06-03T17:13:57.023Z NovaPharmaNews en 2026-06-03T17:07:37.783Z China’s Rise in Drug Development Looms Over U.S. Oncology Market oncology, lung cancer https://novapharmanews.com/uploads/articles/china-s-rise-in-drug-development-looms-over-u-s-oncology-market.webp China’s Rise in Drug Development Looms Over U.S. Oncology Market https://novapharmanews.com/eu/news/horizon-scanning-ema-regulatory-updates 2026-06-03T17:40:29.253Z NovaPharmaNews en 2026-06-03T16:59:25.064Z EMA Horizon Scanning: Navigating Regulatory Updates for Future Medicines https://novapharmanews.com/uploads/articles/horizon-scanning-ema-regulatory-updates.webp EMA Horizon Scanning: Navigating Regulatory Updates for Future Medicines https://novapharmanews.com/apac/news/datroway-approved-metastatic-tnbc 2026-06-03T16:51:22.906Z NovaPharmaNews en 2026-06-03T16:51:22.911Z Datroway Approved: A New Hope for Metastatic TNBC Patients Datroway, metastatic TNBC, metastatic triple-negative breast cancer https://novapharmanews.com/uploads/articles/datroway-approved-metastatic-tnbc.webp Datroway Approved: A New Hope for Metastatic TNBC Patients https://novapharmanews.com/eu/news/x4-pharmaceuticals-ema-chmp-positive-opinion-mavorixafor 2026-06-03T19:00:57.485Z NovaPharmaNews en 2026-06-03T16:43:07.991Z X4 Pharmaceuticals Secures Positive EMA CHMP Opinion for Mavorixafor in WHIM Syndrome Mavorixafor, WHIM Syndrome https://novapharmanews.com/uploads/articles/x4-pharmaceuticals-ema-chmp-positive-opinion-mavorixafor.webp X4 Pharmaceuticals Secures Positive EMA CHMP Opinion for Mavorixafor in WHIM Syndrome https://novapharmanews.com/us/news/fda-declines-guidance-foreign-drug-imports 2026-06-03T16:08:21.159Z NovaPharmaNews en 2026-06-03T16:07:48.130Z FDA Declines Guidance on Foreign Drug Imports: Impact on Pharma BD and Investors https://novapharmanews.com/uploads/articles/fda-declines-guidance-foreign-drug-imports.webp FDA Declines Guidance on Foreign Drug Imports: Impact on Pharma BD and Investors https://novapharmanews.com/eu/news/privosegtor-ema-prime-optic-neuritis 2026-06-03T16:04:42.676Z NovaPharmaNews en 2026-06-03T16:04:42.681Z Privosegtor Secures EMA PRIME Designation for Optic Neuritis Treatment optic neuritis https://novapharmanews.com/uploads/articles/privosegtor-ema-prime-optic-neuritis.webp Privosegtor Secures EMA PRIME Designation for Optic Neuritis Treatment https://novapharmanews.com/eu/news/arrowhead-pharmaceuticals-positive-cardiometabolic-data-european-a 2026-06-03T20:40:22.617Z NovaPharmaNews en 2026-06-03T15:44:55.661Z Arrowhead Pharmaceuticals Presents Positive Cardiometabolic Data at European A Meeting Cardiometabolic disorders https://novapharmanews.com/uploads/articles/arrowhead-pharmaceuticals-positive-cardiometabolic-data-european-a.webp Arrowhead Pharmaceuticals Presents Positive Cardiometabolic Data at European A Meeting https://novapharmanews.com/eu/news/teva-olan-ema-acceptance 2026-06-03T18:22:36.976Z NovaPharmaNews en 2026-06-03T15:33:17.329Z Teva's Olan EMA Application Acceptance: Strategic Implications for Pharma Olan https://novapharmanews.com/uploads/articles/teva-olan-ema-acceptance.webp Teva's Olan EMA Application Acceptance: Strategic Implications for Pharma https://novapharmanews.com/eu/news/florian-lordick-esmo-president-2026-elections-open 2026-06-03T18:05:34.123Z NovaPharmaNews en 2026-06-03T15:30:06.756Z Florian Lordick Elected 2026 ESMO President: Implications for Global Oncology oncology https://novapharmanews.com/uploads/articles/florian-lordick-elected-2026-esmo-president-implications-for-global-oncology.webp Florian Lordick Elected 2026 ESMO President: Implications for Global Oncology https://novapharmanews.com/us/news/ophthalmology-pipeline-milestones-q2-2026 2026-06-03T15:59:49.056Z NovaPharmaNews en 2026-06-03T14:03:59.687Z Ophthalmology Pipeline Milestones for Q2 2026: Key Catalysts and Investor Insights ophthalmology https://novapharmanews.com/uploads/articles/ophthalmology-pipeline-milestones-q2-2026.webp Ophthalmology Pipeline Milestones for Q2 2026: Key Catalysts and Investor Insights https://novapharmanews.com/eu/news/ema-approves-novo-wegovy-weight-loss-drug 2026-06-03T18:58:22.814Z NovaPharmaNews en 2026-06-03T13:59:34.566Z EMA Approves Novo's Wegovy: A Game Changer in Weight Loss Novo, Wegovy, Game, Changer, Weight, Loss https://novapharmanews.com/uploads/articles/ema-approves-novo-s-wegovy-a-game-changer-in-weight-loss.webp EMA Approves Novo's Wegovy: A Game Changer in Weight Loss https://novapharmanews.com/us/news/vir-biotechnology-stock-board-reshuffle-governance-votes 2026-06-03T20:12:48.159Z NovaPharmaNews en 2026-06-03T13:46:17.526Z Vir Biotechnology Stock: Board Reshuffle and Governance Votes Post-AGM https://novapharmanews.com/uploads/articles/vir-biotechnology-stock-board-reshuffle-governance-votes.webp Vir Biotechnology Stock: Board Reshuffle and Governance Votes Post-AGM https://novapharmanews.com/apac/news/big-pharma-china-trials-scrutiny-oncology 2026-06-03T17:29:53.107Z NovaPharmaNews en 2026-06-03T13:41:04.136Z Big Pharma's China Oncology Trials: Navigating a Landscape of Reduced Scrutiny oncology https://novapharmanews.com/uploads/articles/big-pharma-china-trials-scrutiny-oncology.webp Big Pharma's China Oncology Trials: Navigating a Landscape of Reduced Scrutiny https://novapharmanews.com/apac/news/premia-lind-lind-asia-ai-clinical-trials 2026-06-03T14:08:53.772Z NovaPharmaNews en 2026-06-03T12:54:19.518Z PREMIA and Lind Launch Lind Asia to Revolutionize Clinical Trials with AI https://novapharmanews.com/uploads/articles/premia-lind-lind-asia-ai-clinical-trials.webp PREMIA and Lind Launch Lind Asia to Revolutionize Clinical Trials with AI https://novapharmanews.com/eu/news/definitive-trial-milestone-50-percent-recruitment 2026-06-03T13:42:26.442Z NovaPharmaNews en 2026-06-03T12:34:07.717Z DEFINITIVE Trial Milestone: 50% Recruitment Achieved oncology https://novapharmanews.com/uploads/articles/definitive-trial-milestone-50-recruitment-achieved.webp DEFINITIVE Trial Milestone: 50% Recruitment Achieved https://novapharmanews.com/apac/news/kissei-pharmaceutical-halts-tavneos-use-amid-deaths 2026-06-03T16:39:14.467Z NovaPharmaNews en 2026-06-03T12:29:04.104Z Kissei Pharmaceutical Halts Tavneos Use Amid Deaths Tavneos https://novapharmanews.com/uploads/articles/kissei-pharmaceutical-halts-tavneos-use-amid-deaths.webp Kissei Pharmaceutical Halts Tavneos Use Amid Deaths https://novapharmanews.com/us/news/strengths-and-limitations-of-real-world-data-from-electronic-health-records-and-92ed37a9 2026-06-03T20:27:59.414Z NovaPharmaNews en 2026-06-03T12:17:43.536Z Real-World Data from EHRs and Claims: Strengths, Limitations, and Regulatory Impact https://novapharmanews.com/uploads/articles/strengths-and-limitations-of-real-world-data-from-electronic-health-records-and-92ed37a9.webp Real-World Data from EHRs and Claims: Strengths, Limitations, and Regulatory Impact https://novapharmanews.com/us/news/the-common-fund-data-ecosystem-cfde-449d7791 2026-06-03T16:26:24.666Z NovaPharmaNews en 2026-06-03T12:13:10.842Z The Common Fund Data Ecosystem (CFDE) https://novapharmanews.com/uploads/articles/the-common-fund-data-ecosystem-cfde.webp The Common Fund Data Ecosystem (CFDE) https://novapharmanews.com/us/news/the-gross-to-net-squeeze-how-physician-led-patient-education-reduces-gtn-erosion-17169d71 2026-06-03T21:43:34.665Z NovaPharmaNews en 2026-06-03T12:06:39.089Z Physician-Led Patient Education: A Strategy to Mitigate the Gross-to-Net Squeeze https://novapharmanews.com/uploads/articles/the-gross-to-net-squeeze-how-physician-led-patient-education-reduces-gtn-erosion-17169d71.webp Physician-Led Patient Education: A Strategy to Mitigate the Gross-to-Net Squeeze https://novapharmanews.com/us/news/a-secure-and-intelligent-drug-delivery-model-integrating-neural-networks-with-bl-853eecb6 2026-06-03T13:48:00.842Z NovaPharmaNews en 2026-06-03T11:58:42.851Z A Secure And Intelligent Drug Delivery Model Integrating Neural Networks With Blockchain https://novapharmanews.com/uploads/articles/a-secure-and-intelligent-drug-delivery-model-integrating-neural-networks-with-blockchain.webp A Secure And Intelligent Drug Delivery Model Integrating Neural Networks With Blockchain https://novapharmanews.com/us/news/the-market-for-monoclonal-antibodies-trends-challenges-and-opportunities-7a342d06 2026-06-03T13:00:59.052Z NovaPharmaNews en 2026-06-03T11:51:33.317Z The Market for Monoclonal Antibodies: Trends, Challenges, and Opportunities in 2024 monoclonal antibody, mAb, chronic diseases, autoimmune diseases https://novapharmanews.com/uploads/articles/the-market-for-monoclonal-antibodies-trends-challenges-and-opportunities-7a342d06.webp The Market for Monoclonal Antibodies: Trends, Challenges, and Opportunities in 2024 https://novapharmanews.com/us/news/opinion-the-medical-billing-ai-arms-race-between-providers-and-insurance 2026-06-03T19:37:06.807Z NovaPharmaNews en 2026-06-03T11:24:02.375Z Opinion: The medical-billing AI arms race between providers and insurance https://novapharmanews.com/uploads/articles/opinion-the-medical-billing-ai-arms-race-between-providers-and-insurance.webp Opinion: The medical-billing AI arms race between providers and insurance https://novapharmanews.com/us/news/amish-healthcare-lessons-public-health 2026-06-03T17:30:00.822Z NovaPharmaNews en 2026-06-03T11:24:01.460Z Opinion: The Amish Way of Healthcare Offers Lessons for Public Health https://novapharmanews.com/uploads/articles/amish-healthcare-lessons-public-health.webp Opinion: The Amish Way of Healthcare Offers Lessons for Public Health https://novapharmanews.com/us/news/nih-funding-cuts-ebola-preparedness-global-health 2026-06-03T21:43:33.186Z NovaPharmaNews en 2026-06-03T11:24:00.343Z NIH Funding Cuts Hamper Ebola Preparedness and Global Health Security Ebola https://novapharmanews.com/uploads/articles/nih-funding-cuts-ebola-preparedness-global-health.webp NIH Funding Cuts Hamper Ebola Preparedness and Global Health Security https://novapharmanews.com/us/news/ultra-processed-food-policy-demands-escalate-researchers-cite-systemic-issues 2026-06-03T17:29:55.804Z NovaPharmaNews en 2026-06-03T11:23:59.543Z Ultra-Processed Food Policy Demands Escalate as Researchers Cite Systemic Issues https://novapharmanews.com/uploads/articles/ultra-processed-food-policy-demands-escalate-researchers-cite-systemic-issues.webp Ultra-Processed Food Policy Demands Escalate as Researchers Cite Systemic Issues https://novapharmanews.com/apac/news/pmda-approves-new-pharmaceuticals-medical-devices-whats-new 2026-06-03T13:42:31.163Z NovaPharmaNews en 2026-06-03T03:09:14.935Z PMDA Approves New Pharmaceuticals and Medical Devices: What's New https://novapharmanews.com/uploads/articles/pmda-approves-new-pharmaceuticals-medical-devices-whats-new.webp PMDA Approves New Pharmaceuticals and Medical Devices: What's New https://novapharmanews.com/eu/news/eu-trade-policy-china-pharma-analysis 2026-06-03T17:40:28.526Z NovaPharmaNews en 2026-06-03T03:03:08.551Z EU Bolsters Trade Defenses Against Chinese Imports: A Pharmaceutical Market Analysis https://novapharmanews.com/uploads/articles/eu-trade-policy-china-pharma-analysis.webp EU Bolsters Trade Defenses Against Chinese Imports: A Pharmaceutical Market Analysis https://novapharmanews.com/eu/news/ema-january-drug-approvals-2025 2026-06-03T16:25:55.440Z NovaPharmaNews en 2026-06-03T02:53:30.934Z EMA Approves New Medicines in January: Key Updates for Pharma Investors and BD Teams https://novapharmanews.com/uploads/articles/ema-january-drug-approvals-2025.webp EMA Approves New Medicines in January: Key Updates for Pharma Investors and BD Teams https://novapharmanews.com/eu/news/chmp-drug-approvals-analysis 2026-06-03T16:26:04.368Z NovaPharmaNews en 2026-06-03T02:48:00.650Z CHMP Approves New Medicines: Key Decisions and Implications for the Pharmaceutical Industry https://novapharmanews.com/uploads/articles/chmp-drug-approvals-analysis.webp CHMP Approves New Medicines: Key Decisions and Implications for the Pharmaceutical Industry https://novapharmanews.com/us/news/munck-wilson-mandala-fort-worth-life-sciences-expansion 2026-06-03T17:29:57.050Z NovaPharmaNews en 2026-06-03T02:44:01.027Z Munck Wilson Mandala Expands to Fort Worth, Taps Life Sciences Leader https://novapharmanews.com/uploads/articles/munck-wilson-mandala-fort-worth-life-sciences-expansion.webp Munck Wilson Mandala Expands to Fort Worth, Taps Life Sciences Leader https://novapharmanews.com/us/news/fulcrum-therapeutics-stock-plunges-sickle-cell-drug-discontinuation 2026-06-03T16:24:54.810Z NovaPharmaNews en 2026-06-03T02:40:41.950Z Fulcrum Therapeutics Stock Plummets 54% Following Sickle Cell Drug Discontinuation sickle cell disease https://novapharmanews.com/uploads/articles/fulcrum-therapeutics-stock-plunges-sickle-cell-drug-discontinuation.webp Fulcrum Therapeutics Stock Plummets 54% Following Sickle Cell Drug Discontinuation https://novapharmanews.com/us/news/senior-nih-scientist-research-fellow-charged-with-bringing-deactivated-mpox-virus-into-u-s 2026-06-03T20:53:24.961Z NovaPharmaNews en 2026-06-03T02:39:08.229Z Senior NIH scientist, research fellow charged with bringing deactivated mpox virus into U.S. mpox https://novapharmanews.com/uploads/articles/senior-nih-scientist-research-fellow-charged-with-bringing-deactivated-mpox-virus-into-u-s.webp Senior NIH scientist, research fellow charged with bringing deactivated mpox virus into U.S. https://novapharmanews.com/us/news/cambridge-biotech-merger-acquisition-market-analysis 2026-06-03T16:24:35.027Z NovaPharmaNews en 2026-06-03T02:37:12.765Z Ten-Year-Old Cambridge Biotech Seeks Merger or Acquisition Amidst Market Pressures sickle cell https://novapharmanews.com/uploads/articles/cambridge-biotech-merger-acquisition-market-analysis.webp Ten-Year-Old Cambridge Biotech Seeks Merger or Acquisition Amidst Market Pressures https://novapharmanews.com/us/news/outlook-therapeutics-lytenava-fda-resubmission-60-day-review 2026-06-03T15:43:35.228Z NovaPharmaNews en 2026-06-03T02:07:31.338Z Outlook Therapeutics Resubmits LYTENAVA BLA to FDA, Initiating 60-Day Review LYTENAVA https://novapharmanews.com/uploads/articles/outlook-therapeutics-lytenava-fda-resubmission-60-day-review.webp Outlook Therapeutics Resubmits LYTENAVA BLA to FDA, Initiating 60-Day Review https://novapharmanews.com/us/news/hanmi-signs-licensing-deal-lilly-sonefpeglutide 2026-06-03T17:29:54.651Z NovaPharmaNews en 2026-06-03T01:55:24.362Z Hanmi Signs Licensing Deal with Eli Lilly for Sonefpeglutide, Bolstering GLP-2 Pipeline sonefpeglutide https://novapharmanews.com/uploads/articles/hanmi-signs-licensing-deal-lilly-sonefpeglutide.webp Hanmi Signs Licensing Deal with Eli Lilly for Sonefpeglutide, Bolstering GLP-2 Pipeline https://novapharmanews.com/us/news/fda-final-guidance-pulmonary-tuberculosis-drug-development 2026-06-03T21:43:31.609Z NovaPharmaNews en 2026-06-03T01:49:47.494Z FDA Issues Final Guidance for Pulmonary Tuberculosis Drug Development pulmonary tuberculosis https://novapharmanews.com/uploads/articles/fda-final-guidance-pulmonary-tuberculosis-drug-development.webp FDA Issues Final Guidance for Pulmonary Tuberculosis Drug Development https://novapharmanews.com/us/news/stat-pharmalittle-lilly-340b-ebola-vaccine-funding 2026-06-03T15:30:16.152Z NovaPharmaNews en 2026-06-02T19:37:04.227Z STAT+ Pharmalittle: Lilly's 340B Hospital Threat, Ebola Vaccine Funding, and More Ebola https://novapharmanews.com/uploads/articles/stat-pharmalittle-lilly-340b-ebola-vaccine-funding.webp STAT+ Pharmalittle: Lilly's 340B Hospital Threat, Ebola Vaccine Funding, and More https://novapharmanews.com/us/news/why-us-manufactured-pharmaceutical-packaging-equipment-matters 2026-06-03T20:33:48.131Z NovaPharmaNews en 2026-06-02T16:23:39.037Z Why US-manufactured pharmaceutical packaging equipment matters https://novapharmanews.com/uploads/articles/why-us-manufactured-pharmaceutical-packaging-equipment-matters.webp Why US-manufactured pharmaceutical packaging equipment matters https://novapharmanews.com/us/news/virtual-end-doctors-office-waiting-room 2026-06-03T15:43:44.753Z NovaPharmaNews en 2026-06-02T16:23:38.039Z Opinion: The Virtual End of the Doctor's Office Waiting Room https://novapharmanews.com/uploads/articles/virtual-end-doctors-office-waiting-room.webp Opinion: The Virtual End of the Doctor's Office Waiting Room https://novapharmanews.com/us/news/how-one-state-s-medical-meal-program-lowered-health-care-costs 2026-06-03T16:05:52.196Z NovaPharmaNews en 2026-06-02T16:23:37.423Z How one state’s medical meal program lowered health care costs Ebola vaccine https://novapharmanews.com/uploads/articles/how-one-state-s-medical-meal-program-lowered-health-care-costs.webp How one state’s medical meal program lowered health care costs https://novapharmanews.com/us/news/stat-corporate-medicine-telehealth-crackdown 2026-06-03T18:26:00.646Z NovaPharmaNews en 2026-06-02T12:28:43.909Z STAT+ Report: Corporate Medicine Crackdown Threatens Telehealth Business Models https://novapharmanews.com/uploads/articles/stat-corporate-medicine-telehealth-crackdown.webp STAT+ Report: Corporate Medicine Crackdown Threatens Telehealth Business Models https://novapharmanews.com/apac/news/global-rwe-guidance-regulatory-decision-making-updates 2026-06-03T17:30:01.553Z NovaPharmaNews en 2026-06-02T03:53:12.249Z Global Regulatory Agencies Update Real-World Evidence Guidance for Decision-Making https://novapharmanews.com/uploads/articles/global-rwe-guidance-regulatory-decision-making-updates.webp Global Regulatory Agencies Update Real-World Evidence Guidance for Decision-Making https://novapharmanews.com/apac/news/china-oncology-research-europe-alarm 2026-06-03T11:52:06.162Z NovaPharmaNews en 2026-06-02T03:48:14.665Z China's Ascendancy in Oncology Research Alarms European Oncologists, Threatening Europe's Competitive Edge oncology, cancer https://novapharmanews.com/uploads/articles/china-oncology-research-europe-alarm.webp China's Ascendancy in Oncology Research Alarms European Oncologists, Threatening Europe's Competitive Edge https://novapharmanews.com/apac/news/asco-2026-asian-oncology-innovation-clinical-trials 2026-06-03T18:07:28.562Z NovaPharmaNews en 2026-06-02T03:39:08.824Z ASCO 2026: Asian Oncology Innovation Takes Center Stage, Driving Global Clinical Trial Advancements oncology https://novapharmanews.com/uploads/articles/asco-2026-asian-oncology-innovation-clinical-trials.webp ASCO 2026: Asian Oncology Innovation Takes Center Stage, Driving Global Clinical Trial Advancements https://novapharmanews.com/eu/news/fda-approves-aldosterone-synthase-inhibitor-hypertension 2026-06-03T14:05:40.088Z NovaPharmaNews en 2026-06-02T03:29:11.653Z FDA Approves Baxdrostat (Baxfendy) as First Aldosterone Synthase Inhibitor for Uncontrolled Hypertension baxdrostat, Baxfendy, hypertension https://novapharmanews.com/uploads/articles/fda-approves-aldosterone-synthase-inhibitor-hypertension.webp FDA Approves Baxdrostat (Baxfendy) as First Aldosterone Synthase Inhibitor for Uncontrolled Hypertension https://novapharmanews.com/apac/news/dishman-carbogen-amcis-shanghai-nmpa-gmp-audit 2026-06-03T11:52:10.600Z NovaPharmaNews en 2026-06-02T03:29:11.653Z Dishman Carbogen Amcis Shanghai Site Achieves NMPA GMP Compliance with Zero Findings https://novapharmanews.com/uploads/articles/dishman-carbogen-amcis-shanghai-nmpa-gmp-audit.webp Dishman Carbogen Amcis Shanghai Site Achieves NMPA GMP Compliance with Zero Findings https://novapharmanews.com/us/news/inventiva-leadership-lanifibranor-phase-3-data 2026-06-03T20:03:27.090Z NovaPharmaNews en 2026-06-02T03:29:11.653Z Inventiva Bolsters Executive Team Ahead of Lanifibranor Phase 3 Data lanifibranor https://novapharmanews.com/uploads/articles/inventiva-leadership-lanifibranor-phase-3-data.webp Inventiva Bolsters Executive Team Ahead of Lanifibranor Phase 3 Data https://novapharmanews.com/eu/news/x4-pharmaceuticals-mavorixafor-ema-approval 2026-06-03T20:00:50.064Z NovaPharmaNews en 2026-06-02T03:29:11.653Z X4 Pharmaceuticals' Mavorixafor Receives EMA Approval Recommendation for WHIM Syndrome Mavorixafor https://novapharmanews.com/uploads/articles/x4-pharmaceuticals-mavorixafor-ema-approval.webp X4 Pharmaceuticals' Mavorixafor Receives EMA Approval Recommendation for WHIM Syndrome https://novapharmanews.com/us/news/new-fda-approach-drug-prices-implications 2026-06-03T11:52:08.907Z NovaPharmaNews en 2026-06-02T03:29:11.653Z FDA's New Stance on Drug Pricing: Impact on Approvals and Pharma Strategy https://novapharmanews.com/uploads/articles/new-fda-approach-drug-prices-implications.webp FDA's New Stance on Drug Pricing: Impact on Approvals and Pharma Strategy https://novapharmanews.com/eu/news/italy-fourth-europe-clinical-research-enrollment 2026-06-03T11:52:10.296Z NovaPharmaNews en 2026-06-02T03:29:11.653Z Italy's Clinical Research Landscape: Strengths, Weaknesses, and Strategic Implications https://novapharmanews.com/uploads/articles/italy-fourth-europe-clinical-research-enrollment.webp Italy's Clinical Research Landscape: Strengths, Weaknesses, and Strategic Implications https://novapharmanews.com/us/news/fda-approves-atezolizumab-ctdna-mrd-positive-mibc 2026-06-03T11:52:08.859Z NovaPharmaNews en 2026-06-02T03:29:11.653Z FDA Approves Atezolizumab for ctDNA MRD-Positive MIBC: A New Era for Adjuvant Therapy atezolizumab, muscle invasive bladder cancer https://novapharmanews.com/uploads/articles/fda-approves-atezolizumab-ctdna-mrd-positive-mibc.webp FDA Approves Atezolizumab for ctDNA MRD-Positive MIBC: A New Era for Adjuvant Therapy https://novapharmanews.com/eu/news/datroway-priority-review-metastatic-tnbc 2026-06-03T17:29:56.160Z NovaPharmaNews en 2026-06-02T03:29:11.653Z Datroway Priority Review Fuels Hope for Metastatic Triple-Negative Breast Cancer Patients Datroway, breast cancer, metastatic triple-negative breast cancer https://novapharmanews.com/uploads/articles/datroway-priority-review-metastatic-tnbc.webp Datroway Priority Review Fuels Hope for Metastatic Triple-Negative Breast Cancer Patients https://novapharmanews.com/apac/news/newron-pharmaceuticals-june-investor-conferences 2026-06-03T13:46:50.482Z NovaPharmaNews en 2026-06-02T03:29:11.653Z Newron Pharmaceuticals to Present at Upcoming Investor Conferences https://novapharmanews.com/uploads/articles/newron-pharmaceuticals-june-investor-conferences.webp Newron Pharmaceuticals to Present at Upcoming Investor Conferences https://novapharmanews.com/us/news/longeveron-stockholder-letter-corporate-strategy-2026-goals 2026-06-03T20:48:45.552Z NovaPharmaNews en 2026-06-02T03:29:11.653Z Longeveron Stockholder Letter Outlines 2026 Strategy and Partnership Focus https://novapharmanews.com/uploads/articles/longeveron-stockholder-letter-corporate-strategy-2026-goals.webp Longeveron Stockholder Letter Outlines 2026 Strategy and Partnership Focus https://novapharmanews.com/us/news/fda-draft-guidance-biosimilar-pk-studies 2026-06-03T20:53:09.322Z NovaPharmaNews en 2026-06-02T03:29:11.653Z FDA Draft Guidance Slashes Biosimilar PK Study Costs, Accelerating Market Entry https://novapharmanews.com/uploads/articles/fda-draft-guidance-biosimilar-pk-studies.webp FDA Draft Guidance Slashes Biosimilar PK Study Costs, Accelerating Market Entry https://novapharmanews.com/eu/news/mayer-brown-serb-pharmaceuticals-idefirix-acquisition 2026-06-03T14:34:34.874Z NovaPharmaNews en 2026-06-02T03:29:11.653Z SERB Pharmaceuticals Acquires European and MENA Rights to Idefirix® (imlifidase) from Hansa Biopharma AB Idefirix, imlifidase https://novapharmanews.com/uploads/articles/mayer-brown-serb-pharmaceuticals-idefirix-acquisition.webp SERB Pharmaceuticals Acquires European and MENA Rights to Idefirix® (imlifidase) from Hansa Biopharma AB https://novapharmanews.com/apac/news/beone-medicines-phase-3-herizon-gea-data-nejm 2026-06-03T21:21:33.796Z NovaPharmaNews en 2026-06-02T03:29:11.653Z BeOne Medicines' HERIZON-GEA Phase 3 Data in NEJM: A Deep Dive for Pharma BD and Investors https://novapharmanews.com/uploads/articles/beone-medicines-phase-3-herizon-gea-data-nejm.webp BeOne Medicines' HERIZON-GEA Phase 3 Data in NEJM: A Deep Dive for Pharma BD and Investors https://novapharmanews.com/apac/news/hong-kong-new-drug-approval-process 2026-06-03T19:03:28.155Z NovaPharmaNews en 2026-06-02T03:29:11.653Z Hong Kong Overhauls Drug Approval Process: What Pharma BD Teams Need to Know https://novapharmanews.com/uploads/articles/hong-kong-new-drug-approval-process.webp Hong Kong Overhauls Drug Approval Process: What Pharma BD Teams Need to Know https://novapharmanews.com/us/news/lilly-gilead-pharma-ma-boom-market-analysis 2026-06-03T16:02:36.343Z NovaPharmaNews en 2026-06-02T03:29:11.653Z Lilly and Gilead Drive Pharma M&A Surge: A Strategic Market Analysis cancer https://novapharmanews.com/uploads/articles/lilly-gilead-pharma-ma-boom-market-analysis.webp Lilly and Gilead Drive Pharma M&A Surge: A Strategic Market Analysis https://novapharmanews.com/us/news/fda-expands-market-access-ends-products 2026-06-03T17:40:24.123Z NovaPharmaNews en 2026-06-02T03:29:11.653Z FDA Expands ENDS Market Access: Implications for Pharma BD and Investors https://novapharmanews.com/uploads/articles/fda-expands-market-access-ends-products.webp FDA Expands ENDS Market Access: Implications for Pharma BD and Investors https://novapharmanews.com/eu/news/ema-implements-new-eu-pharma-rules-regulatory-updates 2026-06-03T18:42:37.096Z NovaPharmaNews en 2026-06-02T03:27:44.113Z EMA Initiates Implementation of New EU Pharmaceutical Legislation: What Pharma Needs to Know https://novapharmanews.com/uploads/articles/ema-implements-new-eu-pharma-rules-regulatory-updates.webp EMA Initiates Implementation of New EU Pharmaceutical Legislation: What Pharma Needs to Know https://novapharmanews.com/eu/news/regeneron-pharma-ema-eye-drug-review-wolfe-target-trim 2026-06-03T15:42:02.870Z NovaPharmaNews en 2026-06-02T03:20:47.528Z Regeneron Pharma Stock Holds Steady Amid EMA Eye Drug Review and Analyst Target Adjustment eye drug https://novapharmanews.com/uploads/articles/regeneron-pharma-ema-eye-drug-review-wolfe-target-trim.webp Regeneron Pharma Stock Holds Steady Amid EMA Eye Drug Review and Analyst Target Adjustment https://novapharmanews.com/eu/news/teva-olanzapine-lai-ema-review-schizophrenia 2026-06-03T11:52:13.406Z NovaPharmaNews en 2026-06-02T03:17:52.479Z Teva's Once-Monthly Schizophrenia Shot Enters EMA Review, Signaling New Treatment Option olanzapine, schizophrenia https://novapharmanews.com/uploads/articles/teva-olanzapine-lai-ema-review-schizophrenia.webp Teva's Once-Monthly Schizophrenia Shot Enters EMA Review, Signaling New Treatment Option https://novapharmanews.com/eu/news/asco-2026-european-pharma-astrazeneca-roche-market-analysis 2026-06-03T20:50:46.814Z NovaPharmaNews en 2026-06-02T03:10:06.470Z ASCO 2026: European Pharma's Quiet Showing and What AstraZeneca & Roche Must Address https://novapharmanews.com/uploads/articles/asco-2026-european-pharma-astrazeneca-roche-market-analysis.webp ASCO 2026: European Pharma's Quiet Showing and What AstraZeneca & Roche Must Address https://novapharmanews.com/eu/news/esmo-2025-nmi-bladder-cancer-highlights 2026-06-03T15:41:58.399Z NovaPharmaNews en 2026-06-02T03:05:38.541Z ESMO 2025: Key Advances in Non-Muscle-Invasive Bladder Cancer Shape Future Oncology Strategies oncology, non-muscle-invasive bladder cancer https://novapharmanews.com/uploads/articles/esmo-2025-nmi-bladder-cancer-highlights.webp ESMO 2025: Key Advances in Non-Muscle-Invasive Bladder Cancer Shape Future Oncology Strategies https://novapharmanews.com/eu/news/datroway-trodelvy-first-line-tnbc-battle 2026-06-03T19:21:11.778Z NovaPharmaNews en 2026-06-02T03:00:26.076Z Datroway and Trodelvy Vie for First-Line TNBC Dominance Amidst Evolving Treatment Landscape Datroway, Trodelvy, oncology, breast cancer https://novapharmanews.com/uploads/articles/datroway-trodelvy-first-line-tnbc-battle.webp Datroway and Trodelvy Vie for First-Line TNBC Dominance Amidst Evolving Treatment Landscape https://novapharmanews.com/us/news/citius-pharmaceuticals-stock-update-cancer-anti-infective 2026-06-03T11:52:09.394Z NovaPharmaNews en 2026-06-02T02:57:43.611Z Citius Pharmaceuticals Stock Update: Cancer and Anti-Infective Pipeline Insights cancer, anti-infective https://novapharmanews.com/uploads/articles/citius-pharmaceuticals-stock-update-cancer-anti-infective.webp Citius Pharmaceuticals Stock Update: Cancer and Anti-Infective Pipeline Insights https://novapharmanews.com/eu/news/idorsia-c-diff-vaccine-clinical-progress 2026-06-03T20:20:07.473Z NovaPharmaNews en 2026-06-02T02:47:49.435Z Idorsia's C. difficile Vaccine Shows Continued Positive Clinical Progress IDOR-1134-2831, Clostridioides difficile infection https://novapharmanews.com/uploads/articles/idorsia-c-diff-vaccine-clinical-progress.webp Idorsia's C. difficile Vaccine Shows Continued Positive Clinical Progress https://novapharmanews.com/us/news/fda-guidance-animal-thyroid-products-august-2026 2026-06-03T21:15:55.784Z NovaPharmaNews en 2026-06-02T02:35:54.944Z FDA to Issue Guidance on Animal-Derived Thyroid Products by August 2026, Signaling Regulatory Shift NP Thyroid, Desiccated Thyroid Extract, Graves' Disease https://novapharmanews.com/uploads/articles/fda-guidance-animal-thyroid-products-august-2026.webp FDA to Issue Guidance on Animal-Derived Thyroid Products by August 2026, Signaling Regulatory Shift https://novapharmanews.com/us/news/global-regulatory-roundup-june-1-2026 2026-06-03T21:26:55.882Z NovaPharmaNews en 2026-06-02T02:31:43.284Z Global Regulatory Roundup: Key Updates for June 1, 2026 Dermatologicals, oncology, Neurological, Rare Diseases https://novapharmanews.com/uploads/articles/global-regulatory-roundup-june-1-2026.webp Global Regulatory Roundup: Key Updates for June 1, 2026 https://novapharmanews.com/us/news/biotech-m-and-a-trends-2026-outlook 2026-06-03T18:01:20.945Z NovaPharmaNews en 2026-06-02T02:27:52.983Z Biotech M&A Trends: Navigating the 2026 Outlook for Strategic Growth https://novapharmanews.com/uploads/articles/biotech-m-and-a-trends-2026-outlook.webp Biotech M&A Trends: Navigating the 2026 Outlook for Strategic Growth https://novapharmanews.com/us/news/big-pharma-small-deals-biotech-boon 2026-06-03T11:52:32.370Z NovaPharmaNews en 2026-06-02T02:21:10.753Z Big Pharma's Shift to Smaller Deals Boosts Biotech Sector https://novapharmanews.com/uploads/articles/big-pharma-small-deals-biotech-boon.webp Big Pharma's Shift to Smaller Deals Boosts Biotech Sector https://novapharmanews.com/us/news/rallybio-avenzo-reverse-merger-oncology-deal 2026-06-03T22:05:23.634Z NovaPharmaNews en 2026-06-02T02:18:08.248Z Rallybio Taps Avenzo Therapeutics for Reverse Merger to Advance Oncology Pipeline https://novapharmanews.com/uploads/articles/rallybio-avenzo-reverse-merger-oncology-deal.webp Rallybio Taps Avenzo Therapeutics for Reverse Merger to Advance Oncology Pipeline https://novapharmanews.com/us/news/legend-biotech-asco-data-carvykti-lb2102 2026-06-03T19:14:45.093Z NovaPharmaNews en 2026-06-02T02:06:25.818Z Legend Biotech Presents Promising CARVYKTI and LB2102 Data at ASCO LB2102, CARVYKTI https://novapharmanews.com/uploads/articles/legend-biotech-asco-data-carvykti-lb2102.webp Legend Biotech Presents Promising CARVYKTI and LB2102 Data at ASCO https://novapharmanews.com/us/news/cdc-ebola-containment-clinical-trials-priority 2026-06-03T18:02:10.060Z NovaPharmaNews en 2026-06-02T02:01:43.120Z CDC Prioritizes Ebola Containment, Highlighting Critical Role of Clinical Trials Ebola https://novapharmanews.com/uploads/articles/cdc-ebola-containment-clinical-trials-priority.webp CDC Prioritizes Ebola Containment, Highlighting Critical Role of Clinical Trials https://novapharmanews.com/us/news/asia-biopharma-innovation-epicenter-drug-approvals 2026-06-03T12:26:21.537Z NovaPharmaNews en 2026-06-02T01:50:57.481Z Asia Surges as Biopharma Innovation Hub, Driving Global Drug Approvals https://novapharmanews.com/uploads/articles/asia-biopharma-innovation-epicenter-drug-approvals.webp Asia Surges as Biopharma Innovation Hub, Driving Global Drug Approvals https://novapharmanews.com/us/news/dea-reschedules-marijuana-schedule-iii-expediting-medical-access-research 2026-06-03T15:30:15.235Z NovaPharmaNews en 2026-06-02T01:47:13.789Z DEA Reschedules Marijuana to Schedule III, Expediting Medical Access and Research https://novapharmanews.com/uploads/articles/dea-reschedules-marijuana-schedule-iii-expediting-medical-access-research.webp DEA Reschedules Marijuana to Schedule III, Expediting Medical Access and Research https://novapharmanews.com/us/news/fda-expert-panel-review-peptide-access-compounded-drug-market 2026-06-03T20:40:24.597Z NovaPharmaNews en 2026-06-02T01:42:09.232Z FDA Expert Panel to Review Peptide Access, Impacting Compounded Drug Market https://novapharmanews.com/uploads/articles/fda-expert-panel-review-peptide-access-compounded-drug-market.webp FDA Expert Panel to Review Peptide Access, Impacting Compounded Drug Market https://novapharmanews.com/us/news/elite-pharma-fda-anda-generic-anticoagulant-26b 2026-06-03T11:52:32.445Z NovaPharmaNews en 2026-06-02T01:32:47.226Z Elite Pharma Files FDA ANDA for $26B Generic Blood Thinner, Targeting Key Anticoagulant Market blood thinner https://novapharmanews.com/uploads/articles/elite-pharma-fda-anda-generic-anticoagulant-26b.webp Elite Pharma Files FDA ANDA for $26B Generic Blood Thinner, Targeting Key Anticoagulant Market https://novapharmanews.com/us/news/cms-finalizes-medicaid-work-requirement-rules 2026-06-03T20:36:47.899Z NovaPharmaNews en 2026-06-02T01:22:36.164Z CMS Finalizes Medicaid Work Requirement Rules, Impacting State Programs and Pharma Strategy https://novapharmanews.com/uploads/articles/cms-finalizes-medicaid-work-requirement-rules.webp CMS Finalizes Medicaid Work Requirement Rules, Impacting State Programs and Pharma Strategy https://novapharmanews.com/us/news/medicus-pharma-biotech-showcase-2026 2026-06-03T18:21:44.887Z NovaPharmaNews en 2026-06-01T23:38:28.408Z Medicus Pharma Ltd. to Present at Biotech Showcase 2026, Advancing SkinJect Program https://novapharmanews.com/uploads/articles/medicus-pharma-biotech-showcase-2026.webp Medicus Pharma Ltd. to Present at Biotech Showcase 2026, Advancing SkinJect Program